In critically ill patients with acute kidney injury who are hemodynamically unstable or on vasopressor support, what are the indications for sustained low‑efficiency dialysis (SLED) as opposed to standard intermittent hemodialysis or continuous renal replacement therapy?

Sustained Low-Efficiency Dialysis (SLED) Indications

SLED should be used interchangeably with CRRT for hemodynamically unstable ICU patients with acute kidney injury, as no survival advantage exists for any renal replacement modality, making SLED a practical and cost-effective alternative when CRRT resources are limited. 1

Primary Indications for SLED

Hemodynamic Instability

• SLED provides hemodynamic stability comparable to CRRT through gradual fluid removal over 8-12 hours, making it appropriate for vasopressor-dependent patients who cannot tolerate standard intermittent hemodialysis 1, 2.
• The extended treatment duration (typically 8 hours, 6 days per week) allows for controlled ultrafiltration without the rapid intravascular volume shifts that destabilize critically ill patients 3, 4.

Resource and Infrastructure Limitations

• SLED is indicated when CRRT infrastructure or solutions are unavailable, as it uses standard hemodialysis equipment with modified parameters (blood flow 200 mL/min, dialysate flow 300-350 mL/min) 1, 5.
• The cost advantage is substantial: SLED costs approximately $1,431 per week versus $2,607-$3,089 for CRRT, representing a 45-54% reduction 6, 5.
• During the COVID-19 pandemic, SLED emerged as the preferred alternative when CRRT circuits experienced increased clotting and equipment shortages 7.

Anticoagulation Concerns

• SLED can be performed without systemic anticoagulation in 65% of cases using saline flushes alone, making it ideal for patients at high bleeding risk 5.
• Filter clotting occurs in only 18% of heparinized treatments and 29% of heparin-free treatments, rates that are clinically acceptable 5.
• This anticoagulation-free capability distinguishes SLED from CRRT, which typically requires continuous citrate or heparin 3, 6.

Clinical Equivalence to CRRT

Mortality and Renal Recovery

• No mortality difference exists between SLED and CRRT (adjusted OR 1.07,95% CI 0.56-2.03), with 30-day mortality rates of 54% for SLED versus 61% for CRRT 8.
• Risk of persistent dialysis dependence at 30 days is equivalent (adjusted OR 1.36,95% CI 0.51-3.57) 8.
• The landmark ATN study demonstrated that patients could move between SLED and CRRT as hemodynamic status changed without affecting survival or kidney function recovery 3.

Solute Clearance

• SLED delivers a weekly Kt/V of 8.4±1.8, providing equivalent renal clearance (EKRjc) of 29±6 mL/min, comparable to CRRT's target of 20-25 mL/kg/hour 5.
• When prescribed at 6 days per week, SLED achieves the KDIGO-recommended weekly delivered Kt/V of 3.9 3.
• Phosphate removal averages 1.5 g per treatment, requiring electrolyte monitoring every 2-6 hours initially 5, 1.

Situations Where CRRT Is Preferred Over SLED

Neurological Contraindications

• Acute brain injury with elevated intracranial pressure mandates CRRT because SLED's intermittent nature causes osmotic shifts that can worsen cerebral edema 1, 2.
• Severe cerebral edema requires the continuous, gradual solute removal that only CRRT provides 1, 6.

Extreme Hemodynamic Instability

• When minute-to-minute fluid adjustments are required, CRRT's continuous fine-tuning capability exceeds SLED's capacity 1.
• Patients requiring precise hourly fluid balance control benefit from CRRT's 24-hour continuous operation 6.

Practical Implementation

Technical Setup

• Use uncuffed, non-tunneled dialysis catheters placed in the right internal jugular vein with ultrasound guidance; avoid subclavian placement 1.
• Obtain chest radiography after catheter placement to confirm position and exclude pneumothorax before initiating treatment 1.
• Prescribe bicarbonate-buffered (not lactate-buffered) dialysate, particularly for patients with shock, liver failure, or lactic acidosis 3, 1.

Dosing Strategy

• Target a delivered dose equivalent to 20-25 mL/kg/hour CRRT effluent volume 1, 2.
• Increase the prescribed dose by 20-25% above target because treatment interruptions and filter efficiency decline reduce actual delivery 1, 2.
• Monitor delivered dose frequently rather than assuming the prescription is achieved 3.

Medication and Nutrition Management

• Perform therapeutic drug monitoring for beta-lactam antibiotics and other dialyzable medications to prevent under-dosing 1, 2.
• Provide 1.5-1.7 g/kg/day protein once hemodynamically stable, as SLED removes 10-15 g amino acids daily 1.
• Supplement water-soluble vitamins (thiamine, folate, vitamin C) and monitor electrolytes closely 1.

Common Pitfalls

• Do not assume CRRT is always superior for hemodynamically unstable patients—modality selection should be based on local expertise, resources, and specific clinical scenarios rather than dogma 2, 6.
• Avoid prescribing SLED based on arithmetic summation of Kt/V; kinetic modeling shows that Kt/V 1.3 three times weekly does not equal Kt/V 0.65 six times weekly 3.
• Do not overlook the feasibility constraint: SLED requires dialysis personnel available for extended hours (8-hour sessions, 6 days per week), which may not be practical in all centers 1.